• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2019/07/19
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2019/06/24
Shionogi Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lusutrombopag, a Thrombopoietin Receptor Agonist and Epertinib, an HER2/EGFR Inhibitor
2019/06/19
SHIONOGI AND FERRER CONCLUDE A CONTRACT FOR THE PROMOTION IN SPAIN OF RIZMOIC® (NALDEMEDINE), A THERAPEUTIC AGENT FOR OPIOID-INDUCED CONSTIPATION
2019/06/18
Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019
2019/06/18
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2019/06/18
Shionogi Got Approval of Additional Indication of INTUNIV® in Japan for Treatment of Adult ADHD
2019/06/18
Shionogi to Present Cefiderocol and COT-143 Data at American Society for Microbiology Microbe 2019 Meeting
2019/06/13
Shionogi Purchases All Outstanding Shares of Pionnier following the Conclusion of their Joint Study
2019/06/04
Shionogi Announces Positive Top-Line Results for XOFLUZA® (Baloxavir Marboxil) Phase III Study (BLOCKSTONE)
2019/05/23
“Notice of Convocation of the 154th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 154th Annual General Meeting of Shareholders”
2019/05/22
SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND
2019/05/17
Audio webcasting of FY2018 financial results
2019/05/13
Shionogi & Co., Ltd. releases AMR Position Paper